|
False-negative lesions
|
44 lesions
|
28 lesions
|
14 lesions
|
3 lesions
|
|
• Heterogeneous dense parenchyma
|
27/44, 61.4%
|
20/28, 71.5%
|
–
|
–
|
|
• Single view asymmetries
|
8/44, 18.2%
|
1/28, 3.6%
|
–
|
–
|
|
• Operative bed recurrence
|
4/44, 9.1%
|
2/28, 7.1%
|
–
|
–
|
|
• Non-calcified DCIS
|
3/44, 6.8%
|
3/28, 10.7%
|
–
|
–
|
|
• Bilateral asymmetries
|
2/44, 4.5%
|
2/28, 7.1%
|
–
|
–
|
|
• Non-enhancing malignant lesions
|
–
|
–
|
9/14, 64.3%
|
2/3, 66.6%
|
|
• Faintly enhancing lesions
|
–
|
–
|
5/14, 35.7%
|
1/3, 33.4%
|
|
False-positive lesions
|
66 lesions
|
46 lesions
|
30 lesions
|
30 lesions
|
|
• Heterogeneous dense breast
|
23/66, 34.8%
|
15/46, 32.6%
|
–
|
–
|
|
• Inflammatory lesions
|
21/66, 31.8%
|
15/46, 32.6%
|
17/30, 56.7%
|
17/30, 56.7%
|
|
• Benign masses
|
11/66, 16.7%
|
5/46. 10.9%
|
–
|
–
|
|
• Benign precancerous lesions
|
4/66, 6.1%
|
4/46, 8.7%
|
3/30, 10.0%
|
3/30, 10.0%
|
|
• Asymmetric breasts
|
4/66, 6.1%
|
4/46, 8.7%
|
–
|
–
|
|
• Operative bed scarring
|
3/66, 4.5%
|
3/46, 6.5%
|
–
|
–
|
|
• Benign enhancing lesions
|
–
|
–
|
10/30, 33.3%
|
10/30, 33.3%
|
